Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 7:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 484 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: placebo sterile saline Clear all
Terminated Phase 4 Interventional Results available

Sodium Supplementation and Growth in Very Low Birth Weight Infants

NCT01795638
View directory record Official record
Conditions
Extreme Immaturity
Interventions
Sodium chloride, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Days to 8 Days
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 6, 2020 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

MVA Post-Event: Administration Timing and Boost Study

NCT00437021
View directory record Official record
Conditions
Smallpox
Interventions
Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
7
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

NCT05328726
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GZR-18, Placebo
Drug · Other
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 2 Interventional

A Study of MDX-1100 in Subjects With Active Ulcerative Colitis

NCT00656890
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
sterile saline for injection, MDX-1100
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Port Orange, Florida • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 26, 2026, 7:55 AM EDT
Not listed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

NCT02130882
View directory record Official record
Conditions
Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions
benralizumab, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 26, 2026, 7:55 AM EDT
Withdrawn Phase 2 Interventional

HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis

NCT06623240
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
allogeneic Hope Biosciences adipose-derived mesenchymal stem cells, Normal Saline Solution 0.9%
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 26, 2026, 7:55 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Platelet-rich Plasma for Eyebrows

NCT04018859
View directory record Official record
Conditions
Eyebrow Hypotrichosis
Interventions
Platelet Rich Plasma Prep System, Saline
Device · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B

NCT00764634
View directory record Official record
Conditions
Botulism Vaccine
Interventions
Placebo (USP sterile saline for injection), rBV A/B-40 vaccine
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
6
States / cities
Miami, Florida • Pembroke Pines, Florida • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

NCT04492475
View directory record Official record
Conditions
COVID-19
Interventions
Interferon beta-1a, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
55
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

NCT04461353
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Aerolized Hydroxychloroquine Sulfate, Placebo
Drug · Other
Lead sponsor
Pulmoquine Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

NCT05575492
View directory record Official record
Conditions
Cytomegalovirus
Interventions
mRNA-1647, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
9 Years to 25 Years
Enrollment
873 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
44
States / cities
La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 26, 2026, 7:55 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NCT04746924
View directory record Official record
Conditions
Non-small Cell Lung Cancer, NSCLC
Interventions
Tislelizumab, Ociperlimab, Pembrolizumab, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 26, 2026, 7:55 AM EDT
Recruiting Phase 3 Interventional

Tranexamic Acid in Adult Spinal Deformity Surgery

NCT03553186
View directory record Official record
Conditions
Spinal Deformity, Degenerative Lumbar Spinal Stenosis, Blood Loss, Surgical
Interventions
Tranexamic Acid 100 MG/ML, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DMID 23-0015; Lassa Fever CVD 1000

NCT06546709
View directory record Official record
Conditions
Lassa Fever
Interventions
LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU
Biological · Other
Lead sponsor
Wilbur Chen, MD, MS
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 1 Interventional Results available

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

NCT02432716
View directory record Official record
Conditions
Down Syndrome
Interventions
Insulin glulisine, Saline
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
35 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

NCT04956575
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Placebo, Active Comparator
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Tempe, Arizona • Colton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults

NCT06485258
View directory record Official record
Conditions
Rotavirus Infections
Interventions
3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), Placebo
Biological · Other
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 2 Interventional

Phase IIb Study of Intranasal Glutathione in Parkinson's Disease

NCT02424708
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Reduced Glutathione 100mg, Reduced Glutathione 200mg, Placebo
Drug
Lead sponsor
Bastyr University
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Kenmore, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Sep 26, 2026, 7:55 AM EDT
Withdrawn Phase 4 Interventional

GA/Spinal vs. GA/Spinal/NMB for Operative Repair of Hip Fracture

NCT03226080
View directory record Official record
Conditions
Hip Fractures, Anesthesia, Spinal, Anesthesia, General, Neuromuscular Blockade
Interventions
Rocuronium, Sugammadex, Normal saline
Drug
Lead sponsor
Loyola University
Other
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 2 Interventional Results available

The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

NCT04312997
View directory record Official record
Conditions
COVID-19
Interventions
PUL-042 Inhalation Solution, Placebo
Drug
Lead sponsor
Pulmotect, Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Orange, California • San Bernardino, California • Coral Gables, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 2 Interventional Results available

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

NCT04832971
View directory record Official record
Conditions
Mixed Dyslipidemia
Interventions
ARO-ANG3, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Huntington Park, California • Hialeah, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

NCT04920786
View directory record Official record
Conditions
Alzheimer Disease
Interventions
TB006, Sterile saline (Placebo)
Drug · Other
Lead sponsor
TrueBinding, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 26, 2026, 7:55 AM EDT
Terminated Phase 3 Interventional Results available

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

NCT02697292
View directory record Official record
Conditions
Autoimmune Epilepsy
Interventions
Intravenous Immunoglobulin, Placebos, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 26, 2026, 7:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

NCT04144348
View directory record Official record
Conditions
Human Metapneumovirus and Human Parainfluenza Infection
Interventions
mRNA-1653, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Months to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Idaho Falls, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Sep 26, 2026, 7:55 AM EDT